A Cost-Effectiveness Analysis of Corticosteroid Injections and Open Surgical Release for Trigger Finger.


Journal

The Journal of hand surgery
ISSN: 1531-6564
Titre abrégé: J Hand Surg Am
Pays: United States
ID NLM: 7609631

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 29 03 2019
revised: 14 03 2020
accepted: 14 04 2020
pubmed: 31 5 2020
medline: 29 6 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

To evaluate the cost-effectiveness of corticosteroid injection(s) versus open surgical release for the treatment of trigger finger. Using a US health care payer perspective, we created a decision tree model to estimate the costs and outcomes associated with 4 treatment strategies for trigger finger: offering up to 3 steroid injections before to surgery or immediate open surgical release. Costs were obtained from a large administrative claims database. We calculated expected quality-adjusted life-years for each treatment strategy, which were compared using incremental cost-effectiveness ratios. Separate analyses were performed for commercially insured and Medicare Advantage patients. We performed a probabilistic sensitivity analysis using 10,000 second-order Monte Carlo simulations that simultaneously sampled from the uncertainty distributions of all model inputs. Offering 3 steroid injections before surgery was the optimal strategy for both commercially insured and Medicare Advantage patients. The probabilistic sensitivity analysis showed that this strategy was cost-effective 67% and 59% of the time for commercially insured and Medicare Advantage patients, respectively. Our results were sensitive to the probability of injection site fat necrosis, success rate of steroid injections, time to symptom relief after a steroid injection, and cost of treatment. Immediate surgical release became cost-effective when the cost of surgery was below $902 or $853 for commercially insured and Medicare Advantage patients, respectively. Multiple treatment strategies exist for treating trigger finger, and our cost-effectiveness analysis helps define the relative value of different approaches. From a health care payer perspective, offering 3 steroid injections before surgery is a cost-effective strategy. Economic and Decision Analyses II.

Identifiants

pubmed: 32471754
pii: S0363-5023(20)30210-0
doi: 10.1016/j.jhsa.2020.04.008
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

597-609.e7

Informations de copyright

Copyright © 2020 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Auteurs

Thompson Zhuang (T)

VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA; School of Medicine, Stanford University, Redwood City, CA.

Sandy Wong (S)

School of Medicine, Stanford University, Redwood City, CA.

Rhonda Aoki (R)

Stanford University, Redwood City, CA.

Edric Zeng (E)

Stanford University, Redwood City, CA.

Seul Ku (S)

VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA; School of Medicine, Stanford University, Redwood City, CA.

Robin N Kamal (RN)

VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA. Electronic address: rnkamal@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH